drugset / Trial / NCT03181503
Safety and Efficacy of Nemolizumab in PN
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.
Timeline
- Start
- 2017-10-02
- Primary completion
- 2018-09-26
- Completion
- 2018-09-26
Publications
- Kwatra SG, Rodriguez D, Dias-Barbosa C, Budhiarso I, Fofana F, Vernon M, Gabriel S, Piketty C, Puelles J. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis. Dermatol Ther (Heidelb). 2023 Oct;13(10):2403-2416. doi: 10.1007/s13555-023-00999-9. Epub 2023 Aug 24.
- Stander S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J, Bieber T, Misery L, Wollenberg A, Reich A, Ahmad F, Piketty C. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med. 2020 Feb 20;382(8):706-716. doi: 10.1056/NEJMoa1908316.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemolizumab | Monoclonal antibody | 0.5 mg/kg | Subcutaneous |